QBR202 / Quaerite Biopharm - LARVOL DELTA

QBR202, An Albumin-Complexed Tri-Specific Nanobody, Demonstrates Extended Efficacy and Favorable Ocular Biodistribution in Preclinical Models (ARVO 2026) - "Its potency was compared to faricimab using in vitro functional assays. Conclusions The albumin-complexation design of QBR202 confers prolonged ocular retention and targeted tissue delivery, translating to extended efficacy in preclinical CNV models. These findings support QBR202 as a promising multi-specific biologic with the potential to enable longer dosing intervals for retinal vascular diseases, a hypothesis to be evaluated in future clinical trials."

Preclinical • Trispecific • Ophthalmology